Tenofovir Disoproxil Fumarate Tablets
Brand Names: Tenofovir Disoproxil Fumarate Tablets Generic
Methodology & AI Transparency ⓘ
Tenofovir Disoproxil Fumarate Tablets Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within prescription hepatitis b virus nucleoside analog reverse transcriptase inhibitor care, Tenofovir Disoproxil Fumarate Tablets (62135-466; manufactured/labeled by Chartwell RX, LLC.) offers oral-route delivery via 300 mg/1 Tablet, Film Coated with structured clinical follow-up.
- 2 Real-world patient consensus: Zero-PHI community consensus: 76% favorable across 22 logged regimens (Tenofovir Disoproxil Fumarate Tablets Generic).
- 3 Typical cash cost range: Dispensing cost comparison spans $20.40 mail/discount cash up to $49.98 uninsured retail (federal NADAC $0.2938).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Tenofovir Disoproxil Fumarate Tablets): nausea (8.1%), headache (8%), dizziness (6.6%).
Ask our AI Specialists anything about Tenofovir Disoproxil Fumarate Tablets
Tenofovir Disoproxil Fumarate Tablets Mechanism, CYP450 Pathways & DailyMed Monograph
Within prescription hepatitis b virus nucleoside analog reverse transcriptase inhibitor care, Tenofovir Disoproxil Fumarate Tablets (62135-466; manufactured/labeled by Chartwell RX, LLC.) offers oral-route delivery via 300 mg/1 Tablet, Film Coated with structured clinical follow-up.
In oral-route clinical dosing (300 mg/1 Tablet, Film Coated), Tenofovir Disoproxil Fumarate Tablets (manufactured/labeled by Chartwell RX, LLC.; 62135-466) executes hepatitis b virus nucleoside analog reverse transcriptase inhibitor molecular modulation paired with routine metabolic and excretory disposition.
Pharmacokinetic profiling of Tenofovir Disoproxil Fumarate Tablets demonstrates an elimination half-life of Elimination kinetics span 11 to 22 hours per Tenofovir Disoproxil Fumarate Tablets clinical pharmacology with Consistent 47%–59% gastrointestinal absorption profile for Tenofovir Disoproxil Fumarate Tablets systemic bioavailability; clearance proceeds via systemic clearance of tenofovir disoproxil fumarate tablets integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within cmax attained 2–4 hours post-administration of tenofovir disoproxil fumarate tablets.
Titration schedules for Tenofovir Disoproxil Fumarate Tablets (300 mg/1 Tablet, Film Coated → 300 mg/1 Tablet) require excluding contraindicated in patients with prior serious allergic response to tenofovir disoproxil fumarate tablets (ndc 62135-466); severe baseline organ impairment where tenofovir disoproxil fumarate tablets accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (8.1% of reports), headache (8% of reports), dizziness (6.6% of reports) alongside a 76.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Tenofovir Disoproxil Fumarate Tablets in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Tenofovir Disoproxil Fumarate Tablets dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Tenofovir Disoproxil Fumarate Tablets (NDC 62135-466)
- Severe baseline organ impairment where Tenofovir Disoproxil Fumarate Tablets accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (22 Reports)
Tenofovir Disoproxil Fumarate Tablets Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tenofovir Disoproxil Fumarate Tablets)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus: What a 1,306-Participant Study Found Participants with suboptimal (<85%) staying on track with medication to B/F/TAF maintained high levels of VS, whereas suboptimal DTG + 2 NRTI staying on track with medication was associated with lower VS. The Journal of antimicrobial chemotherapy • 2025-01-03 • Phase III Randomized Trial | N = 1,306 | 96/100 | PMID 39556192 ↗ |
| New Insights on Eight-year real-world benefits and safety of tenofovir alafenamide for treatment: What a 866-Participant Study Found Long-term TAF treatment exhibited favourable safety and tolerability with high rates of viral suppression and no development of resistance. Alimentary pharmacology & therapeutics • 2024-12-15 • Phase III Randomized Trial | N = 866 | 93/100 | PMID 39327857 ↗ |
| New Insights on Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil: What a 291-Participant Study Found In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy. The Journal of antimicrobial chemotherapy • 2022-03-31 • Phase III Randomized Trial | N = 291 | 93/100 | PMID 35045168 ↗ |
| New Insights on Week 96 resistance analyses of the once-daily, single-tablet regimen (STR): What a 1,125-Participant Study Found D/C/F/TAF has a high barrier to resistance; no darunavir, primary PI, or tenofovir RAMs occurred through 96 weeks in AMBER and EMERALD. Journal of medical virology • 2021-06-15 • Phase III Randomized Trial | N = 1,125 | 90/100 | PMID 33300183 ↗ |
| Can This Approach Help? Inside the Latest Research on Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety TMF provides sustained antiviral efficacy and maintains a favourable long-term lipid and kidney safety profile. World journal of gastroenterology • 2025-07-14 • Phase III Randomized Trial | N = 53 | 88/100 | PMID 40678712 ↗ |
Tenofovir Disoproxil Fumarate Tablets Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2938/unit (~$8.81/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $49.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $20.40 / mo | View logs ↓ |
Tenofovir Disoproxil Fumarate Tablets Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tenofovir Disoproxil Fumarate Tablets RxNorm Concept ID | RXN-62135466-2958 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2938 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $49.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $20.40 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tenofovir Disoproxil Fumarate Tablets Patient Community, Cohort Filters & Dosage Logs
Deterministic Tenofovir Disoproxil Fumarate Tablets reference combining NIH RxNorm (RXN-62135466-2958), Medicaid NADAC ($0.2938/unit), and anonymous cohort outcomes (76% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tenofovir Disoproxil Fumarate Tablets community threads and patient logs by age, biological sex, dosage, and treatment duration.